“`html
Prophylactic-dose direct oral anticoagulants for non-hospitalised people with COVID-19: A meta-analysis of randomised controlled trials
Summary
- Investigated the impact of prophylactic-dose direct oral anticoagulants (DOACs) in non-hospitalised COVID-19 patients.
- Compared DOACs with placebo or no treatment in six randomised controlled trials involving 4307 patients.
- Found that prophylactic-dose DOAC therapy significantly decreased risks of all-cause mortality and thromboembolic events without increasing major bleeding events.
- Also associated with a reduction in venous thromboembolism without affecting all-cause mortality, arterial thromboembolism, hospitalisations, and clinically relevant nonmajor bleeding.
Overall, prophylactic-dose DOACs could significantly improve clinical outcomes and reduce venous thrombotic events without increasing the risk of major bleeding events compared with placebo or no treatment in non-hospitalised patients with COVID-19.
For more details, you can access the full research here.
“`
